Watson Becomes Actavis: Name Change To Reflect Greater International Focus
Executive Summary
Watson’s merger with Actavis will create the world’s third-largest generic drug company, to be known as Actavis, with significant ex-U.S. market share, especially in the U.K., Nordic countries and Russia.
You may also be interested in...
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches
The world’s generic drug leader has cemented its leadership position for the foreseeable future with the acquisition of Allergan’s generics business. Management outlined how it plans to grow the combined business by taking advantage of its size during an investor briefing.
Forest Labs Targeted By Actavis, Say Unconfirmed Media Reports
Actavis is reported to be in talks to acquire the U.S. specialty firm Forest Labs in a move that would boost Actavis’s branded products business.
Forest Labs Targeted By Actavis, Say Unconfirmed Media Reports
Actavis is reported to be in talks to acquire the U.S. specialty firm Forest Labs in a move that would boost Actavis’s branded products business.